Citius Pharma Shares Surge on U.S. Cancer Immunotherapy Launch

Citius Pharmaceuticals shares are trading higher after the company announced the U.S. launch of its FDA-approved cancer immunotherapy, LYMPHIR, targeting a significant market gap in the treatment of cutaneous T-cell lymphoma.